BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26965290)

  • 1. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
    De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
    Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil.
    Arbex MA; Bonini EH; Kawakame Pirolla G; D'Ambrosio L; Centis R; Migliori GB
    Rev Port Pneumol (2006); 2016; 22(6):337-341. PubMed ID: 27481315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
    Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
    Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.
    Payen MC; Muylle I; Vandenberg O; Mathys V; Delforge M; Van den Wijngaert S; Clumeck N; De Wit S
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):34-39. PubMed ID: 29297423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
    Payen MC; De Wit S; Martin C; Sergysels R; Muylle I; Van Laethem Y; Clumeck N
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):558-60. PubMed ID: 22325421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
    Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
    BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
    Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
    Gonzalo X; Drobniewski F
    J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
    Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
    Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
    Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
    Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Riccardi N; Saderi L; Borroni E; Tagliani E; Cirillo DM; Marchese V; Matteelli A; Piana A; Castellotti P; Ferrarese M; Gualano G; Palmieri F; Girardi E; Codecasa L; Sotgiu G
    Int J Tuberc Lung Dis; 2021 May; 25(5):395-399. PubMed ID: 33977908
    [No Abstract]   [Full Text] [Related]  

  • 17. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
    Roongruangpitayakul C; Chuchottaworn C
    J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.